Tumor suppressor genes of bladder cancer and potential for gene therapy

Advances in Experimental Medicine and Biology

Volumn 539 A, Issue , 2004, Pages 185-191

  Tanaka, Motoyoshi ^a   Grossman, H Barton ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CONNEXIN 26; DOXORUBICIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

BLADDER CARCINOMA; CONFERENCE PAPER; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; HUMAN; MUTATION; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UNITED STATES; WILD TYPE; BLADDER TUMOR; GENETICS; METHODOLOGY; REVIEW;

GENE THERAPY; GENES, TUMOR SUPPRESSOR; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 2342477248     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (56)

1. Aveyard JS, Skilleter A, Habuchi T, Knowles MA: Somatic mutation of PTEN in bladder carcinoma. Br J Cancer, 80:904, 1999.
2. Barbra AD, Hardin J, Ray J, Gage FH: Thymidine kinase-mediated killing of rat brain tumors. J Neurosurg, 79:729, 1993.
3. Bennett MSV, Barrio LC, Bargiello TA, Spray DC, Hertzberg E, Saez JC: Gap junctions: new tools, new answers, new questions. Neuron, 6:305, 1991.
4. Blaese M, Blankenstein T, Brenner M, Cohen-Haguenauer O, Gansbacher B, Russell S, et al: Vectors in cancer therapy: how will they deliver? Cancer Gene Ther, 2:291, 1995.
5. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, et al: Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res, 57:4997, 1997.
6. Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG, et al: Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene, 16:3215, 1998.
7. Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F: Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene, 14:3059, 1997.
8. Carystinos GD, Katabi MM, Laird DW, Galipeau J, Chan H, Alaoui-Jamali MA, et al: Cyclic-AMP induction of gap junctional intercellular communication increases bystander effect in suicide gene therapy. Clin Cancer Res, 5:61, 1999.
9. Cirenei N, Colombo BM, Mesnil M, Benedetti S, Yamasaki H, Finocchiaro G: In vitro and in vivo effects of retrovirus-mediated transfer of the connexin 43 gene in malignant gliomas: consequences for HSVtk/GCV anticancer gene therapy. Gene Ther, 5:1221, 1998.
10. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR: The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol, 158:62, 1997.
11. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science, 256:1550, 1992.
12. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, et al: Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res, 57:4710, 1997.
13. Dermietzel R, Spray DC: Gap junctions in the brain: where, what type, how many and why? Trends Neurosci, 16:186, 1993.
14. Duflot-Dancer A, Piccoli C, Rolland A, Yamasaki H, Mesnil M: Long-term connexin-mediated bystander effect in highly tumorigenic human cells in vivo in herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Ther, 5:1372, 1998.
15. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, et al: In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res, 55:5151, 1995.
16. Eghbali B, Kessler JA, Reid LM, Roy C, Spray DC: Involvement of gap junctions in tumorigenesis: transfection of tumor cells with connexin 32 cDNA retards growth in vivo. Proc Natl Acad Sci USA, 89:10218, 1991.
17. Estin D, Li M, Spray D, Wu JK: Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy. Neurosurgery, 44:361, 1999.
18. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, et al: The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res, 53:5274, 1993.
19. Ghoumari AM, Mouawad R, Zerrouqi A, Nizard C, Provost N, Khayat D, et al: Actions of HSVtk and connexin43 gene delivery on gap junctional communication and drug sensitization in hepatocellular carcinoma. Gene Ther, 5:1114, 1998.
20. Grossman HB, Liebert M, Lee IK, Lee SW: Decreased connexin expression and intercellular communication in human bladder cancer cells. Cancer Res, 54:3062, 1994.
21. Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J: Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res, 57:3660, 1997.
22. Harris MP, Sutjipto S, Wills KN, Hancock W, Cornell D, Johnson DE, et al: Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther, 3:121, 1996.
23. Herr HW: Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol, 15:84, 1997.
24. Hirschi KK, Xu CE, Tsukamoto T, Sager R: Gap junction genes Cx26 and Cx43 individually suppress the cancer phenotype of human mammary cells and restore differentiation potential. Cell Growth Differ, 7:861, 1996.
25. Kim SK, Su LK, Oh Y, Kemp BL, Hong WK, Mao L: Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines. Oncogene, 16:89, 1998.
26. Knuechel R, Siebert-Wellnhofer A, Traub O, Dermietzel R: Connexin expression and intercellular communication in two- and three-dimensional in vitro cultures of human bladder carcinoma. Am J Pathol, 149:1321, 1996.
27. Kozlowski J: Immunotherapy of bladder cancer. J Urol, 162:1581, 1999.
28. Kroft SH, Oyasu R: Biology of disease. Urinary bladder cancer: mechanisms of development and progression. Lab Invest, 71:158, 1994.
29. Lee SW, Tomasetto, JC, Paul DL, Sager R: Transcriptional down-regulation of gap junction proteins blocks junctional communication in mammary cell lines. J Cell Biol, 118:1213, 1992.
30. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (Washington DC), 275:1943, 1997.
31. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet, 16:64, 1997.
32. 32; Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, et al: Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet, 16:333, 1997.
33. McMasters RA, Saylors RL, Jones KE, Hendrix ME, Moyer MP, Drake RR: Lack of bystander killing in herpes simplex virus thymidine kinase-transduced colon cell lines due to deficient connexin43 gap junction formation. Hum Gene Ther, 9:2253, 1998.
34. Mesnil M, Krutovskikh V, Piccoli C, Elfgang C, Traub O, Willecke K, et al: Negative growth control of HeLa cells by connexin gene: connexin species specificity. Cancer Res, 55:629, 1995.
35. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H: Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA, 93:1831, 1996.
36. Mesnil M, Piccoli C, Yamasaki H: A tumor suppressor gene, Cx26, also mediates the bystander effect in HeLa cells. Cancer Res, 57:2929, 1997.
37. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res, 46:5276, 1986.
38. Moolten FL, Wells JM, Heyman RA, Evans RM: Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gene Ther, 1:125, 1990.
39. Naus CC, Bechberger JF, Caveney S, Wilson JX: Expression of gap junction genes in astrocytes and C6 glioma cells. Neurosci Lett, 126:33, 1991.
40. Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin RJ, Hamm H, et al: Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet, 6:1383, 1997.
41. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res, 57:3657, 1997.
42. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Person DZ, et al: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med, 2 985, 1996.
43. Sandberg AA, Berger CS: Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J Urol, 151:545, 1994.
44. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, et al: Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res, 59:1820, 1999.
45. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, et al: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res, 54:784, 1994.
46. Starink TM, van der Veen JP, Arwert, F, de Waal LP, de Lange GG, Gille JJ, et al: The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet, 29:222, 1986.
47. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet, 15:356, 1997.
48. Tanaka M, Müllauer L, Ogiso Y, Fujita H, Moriya S, Furuuchi K, et al: Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res, 55:3228, 1995.
49. Tanaka M, Sazawa A, Shinohara N, Kobayashi Y, Fujioka Y, Koyanagi T, et al: Gelsolin gene therapy by retrovirus producer cells for human bladder cancer in nude mice. Cancer Gene Ther, 6:482, 1999.
50. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, et al:. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res, 57:3935, 1997.
51. Vet JA, Bringuier PP, Schaafsma HE, Witjes JA, Debruyne FM, Schalken JA: Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. Lab. Invest, 73:837, 1995.
52. Vrionis FD, Wu JK, Qi P, Waltzman M, Cherington V, Spray DC: The bystander effect by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther, 4:577, 1997.
53. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res, 57:4183, 1997.
54. Werthman PE, Drazan KE, Rosenthal JT, Khalili R, Shaked A: Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol, 155:753, 1996.
55. Yang L, Chiang Y, Lenz HJ, Danenberg KD, Spears CP, Gordon EM, et al: Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum Gene Ther, 9:719, 1998.
56. Zhu D, Kidder GM, Caveney S, Naus CC: Growth retardation in glioma cells cocultured with cells overexpressing a gap junction protein. Proc Natl Acad Sci USA, 89:10218, 1992.